(Q35034528)

English

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

chronic phase chronic myelogenous leukemia

0 references

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

11

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Srdan Verstovsek

6

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jorge Eduardo Cortes

1

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

10

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Guillermo Garcia-Manero

5

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jenny Pui Shan Wong

9

object named as

Jenny Shan

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Alfonso Quintás-Cardama

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Dan Jones

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Charles Koller

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jody Hiteshew

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

30 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

572-580

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Dynamics of chronic myeloid leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Punish the parent not the progeny.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Treatment of myelogenous leukemia: current status and investigational options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312759

8 July 2018

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Minimal residual disease in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

IFNalpha activates dormant haematopoietic stem cells in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25438

21 January 2018

Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemi

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20886606

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25438

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35034528&oldid=1856485982"